ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Akeso and Fosun Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AkesoFosun Pharma
studies on the registry166202
open to participants now6786
phase 3 studies under way2523
reach primary completion within a year2939
programswith a study of their own in two years1748+18 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAkesoFosun Pharma
Phase 1

Akeso: 6 of its 17 programs at phase 1

  1. AK 135phase 1
  2. AK150phase 1
  3. AK152phase 1
  4. AK154phase 1
  5. AK157D1 for injectionphase 1

and 1 more — sign in to see them all

35%

Fosun Pharma: 26 of its 48 programs at phase 1

  1. HLX319phase 1
  2. Anti-PD-1/IL-2 Fusion Protein TEV-56278phase 1
  3. Cetuximabphase 1
  4. FXS0260phase 1
  5. FXS0683phase 1

and 21 more — sign in to see them all

54%
Phase 2

Akeso: 5 of its 17 programs at phase 2

  1. AK139phase 2
  2. AK138D1phase 2
  3. AK146D1phase 2
  4. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2
  5. tinengotinibphase 2
29%

Fosun Pharma: 9 of its 48 programs at phase 2

  1. BRAF V600E Inhibitor HLX208phase 2
  2. Bcl-2 Inhibitor LOXO-338phase 2
  3. FKC289phase 2
  4. FXR0906phase 2
  5. XH-S003 Capsulephase 2

and 4 more — sign in to see them all

19%
Phase 3

Akeso: 6 of its 17 programs at phase 3

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. ligufalimabphase 3
  4. AK120phase 3
  5. ebronucimabphase 3

and 1 more — sign in to see them all

35%

Fosun Pharma: 13 of its 48 programs at phase 3

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. luvometinibphase 3
  5. dulpatatugphase 3

and 8 more — sign in to see them all

27%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Akeso8 readouts · 1 phase 3

Akeso, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cadonilimabphase 3 · Nov 0 · NCT06341335

Akeso, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2 · Dec 0 · NCT06943820
  2. ivonescimabphase 3 · Dec 0 · NCT05689853
  3. AK139phase 2 · Dec 27 · NCT07436221
  4. ligufalimabphase 3 · Dec 30 · NCT05227664
····

Akeso, May ’27: 1 program whose next study reaches primary completion

  1. tinengotinibphase 2 · May 10 · NCT07052253

Akeso, Jun ’27: 1 program whose next study reaches primary completion

  1. AK152phase 1 · Jun 0 · NCT07301502
··

Akeso, Sep ’27: 1 program whose next study reaches primary completion

  1. AK146D1phase 2 · Sep 1 · NCT07591090
·
Fosun Pharma21 readouts · 3 phase 3

Fosun Pharma, Nov ’26: 2 programs whose next study reaches primary completion

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3 · Nov 22 · NCT06839066
  2. FKC876early phase 1 · Nov 30 · NCT07606937

Fosun Pharma, Dec ’26: 2 programs whose next study reaches primary completion

  1. HLX13phase 3 · Dec 0 · NCT07176650
  2. Bcl-2 Inhibitor LOXO-338phase 2 · Dec 1 · NCT06858618

Fosun Pharma, Jan ’27: 1 program whose next study reaches primary completion

  1. HLX29phase 1 · Jan 31 · NCT07776132

Fosun Pharma, Feb ’27: 1 program whose next study reaches primary completion

  1. FXS5626phase 3 · Feb 28 · NCT07552012

Fosun Pharma, Mar ’27: 2 programs whose next study reaches primary completion

  1. HLX48phase 1 · Mar 0 · NCT07473726
  2. HLX37phase 3 · Mar 30 · NCT07274813

Fosun Pharma, Apr ’27: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. HLX17phase 3 · Apr 9 · NCT06847334
  2. HLX319phase 1 · Apr 23 · NCT07601620
  3. FXS887phase 1 · Apr 28 · NCT07345637
  4. luvometinibphase 3 · Apr 30 · NCT07004075

Fosun Pharma, May ’27: 1 program whose next study reaches primary completion

  1. HLX15phase 3 · May 25 · NCT07477587

Fosun Pharma, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. dulpatatugphase 3 · Jun 1 · NCT06532006
  2. HLX3902phase 1 · Jun 29 · NCT07533708
  3. Cetuximabphase 1 · Jun 30 · NCT07543471

Fosun Pharma, Jul ’27: 1 program whose next study reaches primary completion

  1. pimurutamabphase 3 · Jul 28 · NCT07358585

Fosun Pharma, Aug ’27: 1 program whose next study reaches primary completion

  1. HLX18phase 1 · Aug 12 · NCT07518043

Fosun Pharma, Sep ’27: 3 programs whose next study reaches primary completion

  1. FXS6837phase 3 · Sep 12 · NCT07502638
  2. HLX109phase 1 · Sep 20 · NCT07935941
  3. FXR0906phase 2 · Sep 24 · NCT07766759
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Akeso

New programs 2

Reached a new phase 0

None

Study stopped 1

Primary completion later 1

Fosun Pharma

New programs 4

  • HLX49phase 1 · first study · Nov 12
  • FXS0260phase 1 · first study · Oct 25
  • HLX109phase 1 · first study · Oct 18
  • FXS4640phase 1 · first study · Sep 23

Reached a new phase 3

  • FXR0906phase 2 · Oct 13
  • HLX37phase 3 · Oct 4 · Carcinoma, Non-Small-Cell Lung
  • FXS5626phase 3 · Sep 17 · Uveitis

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 15 in all. A program counts in each condition its studies name most.

ConditionAkesoFosun Pharma
Carcinoma, Non-Small-Cell Lungboth · compare here

Akeso in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. AK138D1phase 2

Their studies: Akeso’s studies of Carcinoma, Non-Small-Cell Lung in search

Fosun Pharma in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. HLX17phase 3
  5. HLX37phase 3

and 6 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Akeso in Breast Neoplasms: 3 programs

  1. AK138D1phase 2
  2. AK146D1phase 2
  3. tinengotinibphase 2

Their studies: Akeso’s studies of Breast Neoplasms in search

Fosun Pharma in Breast Neoplasms: 6 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. dulpatatugphase 3
  3. HLX87phase 3
  4. hx22phase 3
  5. HLX319phase 1

and 1 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Akeso in Colorectal Neoplasms: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Colorectal Neoplasms in search

Fosun Pharma in Colorectal Neoplasms: 5 programs

  1. serplulimabphase 3
  2. BRAF V600E Inhibitor HLX208phase 2
  3. Folfox protocolphase 2
  4. XS-03phase 2
  5. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Colorectal Neoplasms in search

Neoplasmsboth · compare here

Akeso in Neoplasms: 1 program

  1. ligufalimabphase 3

Their studies: Akeso’s studies of Neoplasms in search

Fosun Pharma in Neoplasms: 5 programs

  1. anlotinibphase 2
  2. Folfox protocolphase 2
  3. Cetuximabphase 1
  4. HLX05phase 1
  5. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Neoplasms in search

Small Cell Lung Carcinomaboth · compare here

Akeso in Small Cell Lung Carcinoma: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Small Cell Lung Carcinoma in search

Fosun Pharma in Small Cell Lung Carcinoma: 3 programs

  1. serplulimabphase 3
  2. anlotinibphase 2
  3. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Small Cell Lung Carcinoma in search

Stomach Neoplasmsboth · compare here

Akeso in Stomach Neoplasms: 1 program

  1. cadonilimabphase 3

Their studies: Akeso’s studies of Stomach Neoplasms in search

Fosun Pharma in Stomach Neoplasms: 3 programs

  1. serplulimabphase 3
  2. dulpatatugphase 3
  3. Folfox protocolphase 2

Their studies: Fosun Pharma’s studies of Stomach Neoplasms in search

Triple Negative Breast Neoplasmsboth · compare here

Akeso in Triple Negative Breast Neoplasms: 3 programs

  1. ivonescimabphase 3
  2. ligufalimabphase 3
  3. tinengotinibphase 2

Their studies: Akeso’s studies of Triple Negative Breast Neoplasms in search

Fosun Pharma in Triple Negative Breast Neoplasms: 1 program

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3

Their studies: Fosun Pharma’s studies of Triple Negative Breast Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

Akeso in Carcinoma, Hepatocellular: 2 programs

  1. cadonilimabphase 3
  2. tinengotinibphase 2

Their studies: Akeso’s studies of Carcinoma, Hepatocellular in search

Fosun Pharma in Carcinoma, Hepatocellular: 1 program

  1. HLX13phase 3

Their studies: Fosun Pharma’s studies of Carcinoma, Hepatocellular in search

Pancreatic Neoplasmsboth · compare here

Akeso in Pancreatic Neoplasms: 2 programs

  1. ligufalimabphase 3
  2. AK154phase 1

Their studies: Akeso’s studies of Pancreatic Neoplasms in search

Fosun Pharma in Pancreatic Neoplasms: 1 program

  1. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Pancreatic Neoplasms in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

Akeso in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2

Their studies: Akeso’s studies of Squamous Cell Carcinoma of Head and Neck in search

Fosun Pharma in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. pimurutamabphase 3
  2. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Squamous Cell Carcinoma of Head and Neck in search

Uterine Cervical Neoplasmsboth · compare here

Akeso in Uterine Cervical Neoplasms: 1 program

  1. cadonilimabphase 3

Their studies: Akeso’s studies of Uterine Cervical Neoplasms in search

Fosun Pharma in Uterine Cervical Neoplasms: 2 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. bizalimogene ralaplasmidno phase

Their studies: Fosun Pharma’s studies of Uterine Cervical Neoplasms in search

Alzheimer Diseaseboth · compare here

Akeso in Alzheimer Disease: 1 program

  1. AK152phase 1

Their studies: Akeso’s studies of Alzheimer Disease in search

Fosun Pharma in Alzheimer Disease: 1 program

  1. GV-971no phase

Their studies: Fosun Pharma’s studies of Alzheimer Disease in search

Cholangiocarcinomaboth · compare here

Akeso in Cholangiocarcinoma: 1 program

  1. tinengotinibphase 2

Their studies: Akeso’s studies of Cholangiocarcinoma in search

Fosun Pharma in Cholangiocarcinoma: 1 program

  1. Folfox protocolphase 2

Their studies: Fosun Pharma’s studies of Cholangiocarcinoma in search

Leukemia, Myeloid, Acuteboth · compare here

Akeso in Leukemia, Myeloid, Acute: 1 program

  1. ligufalimabphase 3

Their studies: Akeso’s studies of Leukemia, Myeloid, Acute in search

Fosun Pharma in Leukemia, Myeloid, Acute: 1 program

  1. Bcl-2 Inhibitor LOXO-338phase 2

Their studies: Fosun Pharma’s studies of Leukemia, Myeloid, Acute in search

Ovarian Neoplasmsboth · compare here

Akeso in Ovarian Neoplasms: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Ovarian Neoplasms in search

Fosun Pharma in Ovarian Neoplasms: 1 program

  1. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Ovarian Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Akeso 4 of 17 · Fosun Pharma 25 of 48 programs (11 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Fosun Pharma: 18).